%D8%AF%D9%88%D8%B3%D9%8A%D8%AA%D8%A7%D9%83%D8%B3%D9%8A%D9%84DocetaxelDocetacselDocetaxelDocetaxelDocetaxelDotsetakseel%D8%AF%D9%88%D8%B3%D9%87_%D8%AA%D8%A7%DA%A9%D8%B3%D9%84DosetakseliDoc%C3%A9taxelDocetaxelDoksetakselDocetaxel%E3%83%89%E3%82%BB%E3%82%BF%E3%82%AD%E3%82%BB%E3%83%ABDocetaxel%E0%AC%A1%E0%AD%8B%E0%AC%B8%E0%AD%87%E0%AC%9F%E0%AC%BE%E0%AC%95%E0%AC%B8%E0%AD%87%E0%AC%B2DocetakselDocetaxelDocetaxel%D0%94%D0%BE%D1%86%D0%B5%D1%82%D0%B0%D0%BA%D1%81%D0%B5%D0%BBDocetakselDocetakselDocetaksel%D0%94%D0%BE%D1%86%D0%B5%D1%82%D0%B0%D0%BA%D1%81%D0%B5%D0%BBDocetaxelQ420436%E6%AD%90%E6%B4%B2%E7%B4%AB%E6%9D%89%E9%86%87
about
P3781
Docetaxel Followed by Provenge in Metastatic Prostate CancerOrteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel TherapyReolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage TherapyKetoconazole Plus Docetaxel to Treat Prostate CancerA Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerRadiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignMaximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHNAnlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung CancerAdjuvant Palbociclib in Elderly Patients With Breast CancermFLOT Chemotherapy as First-line Treatment in GCPostoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell CarcinomaGemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory OsteosarcomaChemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial TractThe Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric CancerTC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast CancerEpirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast CancerPhase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast CancerA Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate CancerAbiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyTarceva Italian Lung Optimization tRialTrial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast CancerRandomised Study of Concomitant Radiochemotherapy in Non-small Cell Lung CancerPredictors for Response to Dose-dense Docetaxel and Epirubicin Breast CancerE3 Breast Cancer Taxotere CombinationPhase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate CancerTAC Versus TC for Adjuvant Breast CancerSafety of LBH589 Alone and in Combination With IV Docetaxel and PrednisoneAdj TC + Herceptin Early Stage Breast CancerA Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast CancerIntermittent Chemotherapy With or Without GM-CSF for Metastatic HPRCTreatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer PatientsImatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell CancerAn Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based ChemotherapyA Phase II Study of Weekly Docetaxel and Topotecan in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian CancerPARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of ResponseInvestigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid TumorA Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
P4844
Antineoplastic drug exposure in an ambulatory setting: a pilot studyClinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancerNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerNeoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.
P921
Q128581-AEE08912-02DD-4D47-8A11-0E944CE700C4Q172341-0764842F-F274-4A0F-9F31-45BA8469E284Q1783924-D0C6CB73-99EE-40B0-99E3-574C93B3470AQ180614-4D19CD28-2B22-4C41-A515-433CB564EFE4Q18553680-BE812539-0B32-4313-A73E-7316C7EFAB1CQ189588-B5B9250B-BA9D-4358-8142-C000A942D1EDQ212961-6C048B1C-71DE-4672-B7B8-2669457CB579Q3658562-5B973F73-09F4-4B32-910D-BD6E880FA823
P2176
Q58407616-8b991b58-48ef-184f-b061-18b8c6bb3e2aQ61707448-822A8022-4D68-431A-980E-527517361E4DQ61713084-BD559A03-BBC0-4F88-9B89-3951B09E452CQ61865364-C9F367CD-1BE6-49D4-B534-1B55D5A34918Q61894354-BC2AFC06-B3FD-4FEB-B5A8-806E58A75387Q61894513-7604329A-3705-4F3E-B7DB-2F1C53F8D202Q61894641-ED383ABB-439F-472D-8526-D8E4BB283FBFQ61894670-C4608A58-89C5-4D9A-A138-35FADB599AACQ61902306-217BFDD1-0834-4125-BF8B-AF25955ABF8CQ61906992-2AE082D7-D08B-4D4E-9308-88B162876A2DQ61907176-882B414C-847B-480D-A834-B2A09701BB8EQ61907680-31F09A57-03B2-4310-8800-393B61A89A1DQ61907882-120A2201-A294-4057-BB9B-66C0E3D39046Q61909207-07248177-11DF-43F4-A98C-143604295CFDQ61909378-144A6A03-A1AE-4A3E-A885-2BB03B3BD12DQ61909698-FCA99386-0B1A-4750-AACC-975E5CD24370Q61909717-2DCD81FE-7937-4841-A74F-B7AF621D4F23Q61914391-4BC95CD9-8026-4A54-BD0C-6ABECC4792ACQ61914439-5BB12162-8921-4ABA-A93A-38B29EE272D2Q61914768-DDBE3B06-FE86-4FBE-B128-FFC77F8F4566Q61915102-A038EC53-0610-4598-A3F7-87777781C1F3Q61915186-3D10CAB3-1D8F-460A-9691-812CA3648A26Q61915329-9CD819A7-9CAB-40B0-AD0D-2AE3267D2867Q61915591-7DA3356F-BE49-41E0-A740-0C431FC52743Q61917460-7111AA2F-CEDF-412B-BFFC-4B581C0C25A3Q61917689-F7CCE020-068E-4F4B-87B8-90578C0C1E15Q61917710-7AF9C830-27CE-4FE5-8A23-F351D25EE61DQ61917760-578C5BA1-7592-4AE2-92A1-F4C3C8EE03C3Q61917771-044508A0-90DC-4048-BC6E-5E55ACC250BFQ61917781-C791AE3D-D467-4252-82F5-EACE96FF233BQ61918038-35633AEA-9092-41C7-A654-96F4C0BDD363Q61918187-0AB78CAD-E33E-4183-B4E3-E75FC520299DQ61918465-70C29C51-A5E2-4584-A6C6-7C96FCB93218Q61918507-157ED778-AB21-4D0A-A42C-A6C5C29322BFQ61918521-CDC9F87F-2E26-4547-958B-A866F5E7C2CDQ61918581-D50D0A39-99E5-4EBE-88FA-CAD3E77F1F39Q61920686-74E43750-0949-4C6D-8576-7D840133AEA5Q61920698-C698F50E-D993-4BF4-9EA8-3A6567F92C50Q61920699-6354FB88-8790-4A52-A848-B1F7227233A7Q61920784-558D07F4-5D16-41AA-B26F-682701F6C507
P4844
description
Hợp chất hóa học
@vi
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
Docetaksel
@sh
Docetaksel
@sl
Docetaxel
@de
Docetaxel
@es
Docetaxel
@gl
Docetaxel
@it
Docetaxel
@ro
Docetaxel
@vi
Doketakseli
@fi
Doksetaksel
@id
type
label
Docetaksel
@sh
Docetaksel
@sl
Docetaxel
@de
Docetaxel
@es
Docetaxel
@gl
Docetaxel
@it
Docetaxel
@ro
Docetaxel
@vi
Doketakseli
@fi
Doksetaksel
@id
altLabel
114977-28-5
@fr
C43H53NO14
@fr
Docecad®
@cy
Docecad®
@en
Docetaxel anhydrous
@en
Docetaxel
@cy
Docetaxel
@en
Docetaxel
@et
Docetaxel
@fr
EmDOC
@cy
prefLabel
Docetaksel
@sh
Docetaksel
@sl
Docetaxel
@de
Docetaxel
@es
Docetaxel
@gl
Docetaxel
@it
Docetaxel
@ro
Docetaxel
@vi
Doketakseli
@fi
Doksetaksel
@id